Nature Communications (Oct 2022)
A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma
- Tira J. Tan,
- W. X. Gladys Ang,
- Who-Whong Wang,
- Hui-Shan Chong,
- Sze Huey Tan,
- Rachael Cheong,
- John Whay-Kuang Chia,
- Nicholas L. Syn,
- Wai Ho Shuen,
- Rebecca Ba,
- Nivashini Kaliaperumal,
- Bijin Au,
- Richard Hopkins,
- Xinhua Li,
- Aaron C. Tan,
- Amanda O. L. Seet,
- John E. Connolly,
- Thaschawee Arkachaisri,
- Valerie Chew,
- Ahmad bin Mohamed Lajam,
- Dianyan Guo,
- Marvin Z. W. Chew,
- Martin Wasser,
- Pavanish Kumar,
- Salvatore Albani,
- Han Chong Toh
Affiliations
- Tira J. Tan
- Division of Medical Oncology, National Cancer Centre
- W. X. Gladys Ang
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Who-Whong Wang
- Division of Medical Oncology, National Cancer Centre
- Hui-Shan Chong
- Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre
- Sze Huey Tan
- Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre
- Rachael Cheong
- Division of Medical Oncology, National Cancer Centre
- John Whay-Kuang Chia
- Curie Oncology
- Nicholas L. Syn
- Yong Loo Lin School of Medicine, National University of Singapore
- Wai Ho Shuen
- Division of Medical Oncology, National Cancer Centre
- Rebecca Ba
- Division of Medical Oncology, National Cancer Centre
- Nivashini Kaliaperumal
- Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR)
- Bijin Au
- Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR)
- Richard Hopkins
- Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR)
- Xinhua Li
- Singapore Clinical Research Institute (SCRI)
- Aaron C. Tan
- Division of Medical Oncology, National Cancer Centre
- Amanda O. L. Seet
- Division of Medical Oncology, National Cancer Centre
- John E. Connolly
- Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR)
- Thaschawee Arkachaisri
- Rheumatology and Immunology Service, KK Women’s and Children’s Hospital
- Valerie Chew
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Ahmad bin Mohamed Lajam
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Dianyan Guo
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Marvin Z. W. Chew
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Martin Wasser
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Pavanish Kumar
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Salvatore Albani
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre
- Han Chong Toh
- Division of Medical Oncology, National Cancer Centre
- DOI
- https://doi.org/10.1038/s41467-022-33834-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Ad-sig-hMUC1/ecdCD40L is a recombinant adenovirus vaccine comprising human MUC1 antigen fused to the extracellular domain of the CD40 ligand. Here the authors report the result of a phase I clinical trial of Ad-sig-hMUC1/ecdCD40L in patients with advanced adenocarcinoma.
